
Work Here?
Colossal develops gene editing approaches to revive extinct or endangered species and restore ecological balance. It collects viable DNA samples and edits genes to rebuild traits of lost megafauna, with Woolly Mammoth as a leading project. Its technology translates into practical applications for species recovery and conservation, aiming to kickstart biodiversity and support the biology economy. Distinctive aspects include a focus on de-extinction tied to ecological restoration, leadership from Ben Lamm and George Church, and a strategy that links scientific capability with real-world ecological and economic benefits. The company’s goal is to reawaken lost wilds to help ecosystems recover and allow humanity to coexist with a healthier planet.
Industries
Biotechnology
Company Size
51-200
Company Stage
Series C
Total Funding
$625M
Headquarters
Austin, Texas
Founded
2021
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$625M
Above
Industry Average
Funded Over
8 Rounds
Industry standards
Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Flexible Spending Account/Flexible Spending Account
401(k) Company Match
Paid Parental Leave
Education Reimbursement
Colossal Biosciences innovates with 3d-printed eggs. Colossal Biosciences has made headlines by developing an innovative 3D-printed artificial eggshell, designed to cultivate living chicks outside of traditional eggs. This breakthrough occurred at the company's Dallas headquarters, where researchers observed baby chicks moving and attempting to hatch from transparent plastic constructs rather than organic eggs. The artificial eggshell, more accurately described as a synthetic incubation system, is an oval-shaped lattice coated with a specialized silicone membrane that allows oxygen to permeate, mimicking the natural function of an eggshell. In a unique process, Colossal poured the contents of recently laid chicken eggs into these artificial shells, allowing the embryos to develop under controlled conditions. The transparent design features a viewing window that enables scientists to monitor the chicks' growth. Andrew Pask, the company's Chief Biology Officer, expressed excitement at witnessing life develop outside the womb, emphasizing the potential of this technology not only for avian conservation but also in efforts to resurrect extinct species like the giant moa and the dodo. Colossal's aim is to utilize gene-editing technologies to create animals with desired traits, having already raised substantial funding towards this mission. While the artificial eggshell represents a significant step forward, some experts in the scientific community have raised concerns about the claims surrounding its novelty. Critics argue that the principles behind the technology are not entirely new, referencing previous work in artificial incubation by other researchers. The discussion highlights a broader conversation about the challenges of cross-species genetic manipulation, especially when it comes to larger extinct birds like the moa. As Colossal endeavors to push the boundaries of biotechnology, the collaboration and scrutiny from the scientific community will be critical in navigating the ethical implications and technical hurdles that lie ahead.
Colossal Biosciences, a Texas company working to revive extinct species, has successfully hatched healthy chickens using artificial eggs, marking progress towards resurrecting the dodo and giant moa. The company announced on Tuesday that more than two dozen chicks have been born from its 3D-printed plastic eggs. The artificial eggs replicate natural egg functions and will be scaled up for larger extinct birds. Colossal plans to create dodo and moa embryos using gene-edited cells from the Nicobar pigeon and emu, respectively. Whilst some scientists praise the technology's conservation potential, critics question the ethics and feasibility of de-extinction. They argue the animals may be doomed without suitable habitats and could damage existing ecosystems. Colossal has raised $295 million to date and is also developing artificial wombs for mammals like the woolly mammoth.
A second startup from Dallas billionaire Ben Lamm has achieved unicorn status with a $2 billion valuation in its latest funding round. Lamm, who also co-founded and leads Colossal Biosciences, has seen his new venture reach the milestone valuation. The company focuses on predicting biology, evolution and diseases before they occur. This marks Lamm's second startup to surpass the $1 billion valuation threshold, following his success with Colossal Biosciences.
Colossal Biosciences, which is trying to bring back the wooly mammoth with genetics tech, has spun out its AI startup Astromech at a $2 billion valuation.
Dallas-based Colossal Biosciences has secured $60 million from the United Arab Emirates to build the Colossal BioVault and World Preservation Lab at Dubai's Museum of the Future. The investment is part of Colossal's expanded Series C round, bringing total funding to over $615 million. The facility will house millions of samples representing more than 10,000 species, initially focusing on the 100 most imperiled species not currently preserved elsewhere. Using automated robotics, AI monitoring and cryopreservation technology, the project aims to create a backup system for Earth's biodiversity. The initiative addresses the threat that nearly half of Earth's species could face extinction by 2050. The Dubai facility will eventually form part of a global network of BioVaults. Visitors will observe scientists working in real time on DNA sequencing and cell line preservation.
Find jobs on Simplify and start your career today
Industries
Biotechnology
Company Size
51-200
Company Stage
Series C
Total Funding
$625M
Headquarters
Austin, Texas
Founded
2021
Find jobs on Simplify and start your career today